DISCLAIMER
These codes are currently under development by the LOINC team, and are subject to change prior to inclusion in a public release. It is possible that they may not be published in the next, or any, public release. They are provided here for informational purposes only.
SPECIAL USE
Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release.
Guidance for mapping to SARS-CoV-2 LOINC terms
Full list of LOINCs related to SARS-CoV-2/COVID-19
The page linked above includes an option to export terms in CSV format.
Receive email notices of new Special Use LOINC terms
scroll/swipe to view more columns
| Created On | LOINC | Long Common Name | Special Use | Component | Prop | Time | System | Scale | Method | Shortname |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-03-24 | 96986-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with non-probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Nose | Ord | Non-probe.amp.tar | SARS-CoV-2 N gene Nose Ql NAA+non-probe |
| 2021-03-22 | 96957-6 | SARS-CoV-2 (COVID-19) M gene [Presence] in Upper respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 M gene | PrThr | Pt | Respiratory.upper | Ord | Probe.amp.tar | SARS-CoV-2 M gene Upper resp Ql NAA+prob |
| 2021-03-22 | 96958-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N2 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar.CDC primer-probe set N2 | SARS-CoV-2 N gene Sal Ql NAA N2 |
| 2021-03-11 | 96897-4 | SARS-CoV-2 (COVID-19) RNA panel - Oropharyngeal wash by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA panel | - | Pt | Oropharyngeal wash | - | Probe.amp.tar | SARS-CoV-2 RNA Pnl OPA wash NAA+probe |
| 2021-03-11 | 96898-2 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | SARS-CoV-2 N gene Ct OPA wash Qn NAA+prb |
| 2021-03-11 | 96899-0 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | SARS-CoV-2 ORF1ab Ct OPA wash Qn NAA+prb |
| 2021-03-11 | 96900-6 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | SARS-CoV-2 S gene Ct OPA wash Qn NAA+prb |
| 2021-03-06 | 96894-1 | SARS coronavirus 2 (COVID-19) whole genome sequencing and identification panel - Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 whole genome sequencing & identification panel | - | Pt | XXX | - | Molgen | SARS-CoV-2 Seq and ID Pnl Spec |
| 2021-03-06 | 96895-8 | SARS-CoV-2 (COVID-19) lineage [Identifier] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 lineage | Prid | Pt | XXX | Nom | Molgen | SARS-CoV-2 lineage Spec |
| 2021-03-06 | 96896-6 | SARS coronavirus 2 (COVID-19) clade [Type] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 clade | Type | Pt | XXX | Nom | Molgen | SARS-CoV-2 clade Spec |
| 2021-02-26 | 96874-3 | COVID-19 Immunization note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Immunization note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Immunization note |
| 2021-02-24 | 96829-7 | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen from Donor by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | XXX^Donor | Ord | Probe.amp.tar | SARS-CoV-2 RNA Spec Donr Ql NAA+probe |
| 2021-02-18 | 96797-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Oropharyngeal wash by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Oropharyngeal wash | Ord | Probe.amp.tar | SARS-CoV-2 RNA OPA wash Ql NAA+probe |
| 2021-02-04 | 96766-1 | GISAID sequence accession number | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | GISAID sequence accession number | ID | Pt | Isolate | Nom | GISAID seq accession ID | |
| 2021-02-02 | 96763-8 | SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 E gene Resp Ql NAA+probe |
| 2021-02-02 | 96764-6 | SARS-CoV-2 (COVID-19) E gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | ThreshNum | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 E gene Ct Resp Qn NAA+probe |
| 2021-02-02 | 96765-3 | SARS-CoV-2 (COVID-19) S gene [Presence] in Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | SARS-CoV-2 S gene Sal Ql NAA+probe |
| 2021-01-29 | 96755-4 | SARS-CoV-2 (COVID-19) variant interpretation in Specimen Narrative | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 variant interpretation | Imp | Pt | XXX | Nar | SARS-CoV-2 variant Imp Spec | |
| 2021-01-29 | 96756-2 | SARS-CoV-2 (COVID-19) S gene codon N501= [Presence] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene codon N501= | PrThr | Pt | XXX | Ord | Molgen | SARS-CoV-2 S gene N501= Spec Ql |
| 2021-01-29 | 96757-0 | SARS-CoV-2 (COVID-19) S gene codon N501Y [Presence] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene codon N501Y | PrThr | Pt | XXX | Ord | Molgen | SARS-CoV-2 S gene N501Y Spec Ql |
| 2021-01-14 | 96751-3 | SARS-CoV-2 (COVID-19) S gene mutation detected [Identifier] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene mutation detected | Prid | Pt | XXX | Nom | Molgen | SARS-CoV-2 S gene mut Spec |
| 2021-01-14 | 96752-1 | SARS-CoV-2 (COVID-19) S gene mutation [Presence] in Specimen by Molecular genetics method | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene mutation | PrThr | Pt | XXX | Ord | Molgen | SARS-CoV-2 S gene mut Spec Ql |
| 2021-01-07 | 96742-2 | SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | MCnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 IgG SerPl IA-mCnc |
| 2021-01-06 | 96741-4 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 variant | Type | Pt | XXX | Nom | Sequencing | SARS-CoV-2 variant Spec Seq |
| 2020-12-18 | 96736-4 | COVID-19 Procedure note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Procedure note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Proced note |
| 2020-12-18 | 96737-2 | COVID-19 Consultation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Consultation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Consult note |
| 2020-12-18 | 96738-0 | COVID-19 letter | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 letter | Find | Pt | {Setting} | Doc | {Role} | COVID19 letter |
| 2020-12-18 | 96739-8 | Telehealth COVID-19 note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 note | Find | Pt | Telehealth | Doc | {Role} | Telehealth COVID19 note |
| 2020-12-18 | 96740-6 | COVID-19 note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 note | Find | Pt | {Setting} | Doc | {Role} | COVID19 note |
| 2021-04-01 | 97049-1 | p53 Ab [Mass/volume] in Serum or Plasma by Immunoassay | p53 Ab | MCnc | Pt | Ser/Plas | Qn | IA | p53 Ab SerPl IA-mCnc | |
| 2021-04-01 | 97050-9 | Acinetobacter calcoaceticus-baumannii complex DNA [Presence] by NAA with non-probe detection in Positive blood culture | Acinetobacter calcoaceticus-baumannii complex DNA | PrThr | Pt | Bld.pos growth | Ord | Non-probe.amp.tar | ACB complex DNA Bld Pos Ql NAA+non-probe | |
| 2021-04-01 | 97051-7 | Interferon beta [Mass/volume] in Serum or Plasma | Interferon.beta | MCnc | Pt | Ser/Plas | Qn | IFN-B SerPl-mCnc | ||
| 2021-04-01 | 97052-5 | Chemokine (C-C motif) ligand 2 [Mass/volume] in Serum or Plasma | Chemokine (C-C motif) ligand 2 | MCnc | Pt | Ser/Plas | Qn | CCL2 SerPl-mCnc | ||
| 2021-04-01 | 97053-3 | Macrophage inflammatory protein 1 alpha [Mass/volume] in Serum or Plasma | Macrophage inflammatory protein 1.alpha | MCnc | Pt | Ser/Plas | Qn | MIP-1 alpha SerPl-mCnc | ||
| 2021-04-01 | 97054-1 | Granulocyte monocyte colony stimulating factor [Mass/volume] in Serum or Plasma | Granulocyte monocyte colony stimulating factor | MCnc | Pt | Ser/Plas | Qn | GM-CSF SerPl-mCnc | ||
| 2021-03-31 | 97025-1 | BRAF gene V600 mutations [Identifier] in Tissue by Molecular genetics method Nominal | BRAF gene.p.Val600 mutations | Prid | Pt | Tiss | Nom | Molgen | BRAF p.V600 mutations Tiss | |
| 2021-03-30 | 97024-4 | aPTT mixing study panel - Platelet poor plasma | aPTT mixing study panel | - | Pt | PPP | - | aPTT Mix Pnl PPP | ||
| 2021-03-29 | 97005-3 | Maximum amplitude kaolin+tissue factor induced [Length] in Blood by Resonance TEG | Maximum clot strength amplitude.kaolin+tissue factor induced | Len | Pt | Bld | Qn | Thromboelastography.resonance | MA kaolin+TF Bld Res TEG | |
| 2021-03-29 | 97006-1 | Maximum amplitude kaolin+tissue factor induced [Length] in Blood | Maximum clot strength amplitude.kaolin+tissue factor induced | Len | Pt | Bld | Qn | MA kaolin+TF Bld | ||
| 2021-03-29 | 97007-9 | Clot initiation.kaolin induced [Time] in Blood by Resonance TEG --post heparin neutralization | Clot initiation.kaolin induced^post heparin neutralization | Time | Pt | Bld | Qn | Thromboelastography.resonance | Clot init kaolin ind p hep neut Bld Res | |
| 2021-03-29 | 97008-7 | Clot initiation.kaolin+tissue factor induced [Time] in Blood | Clot initiation.kaolin+tissue factor induced | Time | Pt | Bld | Qn | Clot init kaolin+TF ind Bld | ||
| 2021-03-29 | 97009-5 | Activated clotting time.kaolin+tissue factor induced of Blood by calculation | Activated clotting time.kaolin+tissue factor induced | Time | Pt | Bld | Qn | Calculated | ACT Kaolin+TF Ind Bld Calc | |
| 2021-03-29 | 97010-3 | Clot formation kaolin+tissue factor induced [Time] in Blood | Clot formation.kaolin+tissue factor induced | Time | Pt | Bld | Qn | CFT kaolin+TF ind Bld | ||
| 2021-03-29 | 97011-1 | Clot angle kaolin+tissue factor induced in Blood | Clot angle.kaolin+tissue factor induced | Angle | Pt | Bld | Qn | Clot angle kaolin+TF ind Bld | ||
| 2021-03-29 | 97012-9 | Reduction in kaolin+tissue factor induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude | Reduction in clot strength.kaolin+tissue factor induced^30M post maximum clot amplitude | LenFr | Pt | Bld | Qn | Lysis of kao+TF ind clot 30M p MA LenFr | ||
| 2021-03-29 | 97013-7 | Reduction in kaolin induced clot strength [Length fraction] in Blood by Resonance TEG --30 minutes post maximum clot amplitude | Reduction in clot strength.kaolin induced^30M post maximum clot amplitude | LenFr | Pt | Bld | Qn | Thromboelastography.resonance | Fibrinolysis of kaolin ind clot 30M p MA | |
| 2021-03-29 | 97014-5 | Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood by Resonance TEG | Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited | Len | Pt | Bld | Qn | Thromboelastography.resonance | MA TF ind+IIb-IIIa inh Bld Res TEG | |
| 2021-03-29 | 97015-2 | Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood | Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited | Len | Pt | Bld | Qn | MA TF ind+IIb-IIIa inh Bld | ||
| 2021-03-29 | 97016-0 | Fibrinogen [Mass/volume] in Blood by calculation | Fibrinogen | MCnc | Pt | Bld | Qn | Calculated | Fibrinogen Bld Calc-mCnc | |
| 2021-03-29 | 97018-6 | Maximum amplitude activator F induced [Length] in Blood | Maximum clot strength amplitude.activator F induced | Len | Pt | Bld | Qn | MA ActF Bld | ||
| 2021-03-29 | 97017-8 | Maximum amplitude kaolin induced [Length] in Blood --after addition of heparinase | Maximum clot strength amplitude.kaolin induced^after addition of heparinase | Len | Pt | Bld | Qn | MA kaolin P Hpase Bld | ||
| 2021-03-29 | 97019-4 | Maximum amplitude ADP induced [Length] in Blood | Maximum clot strength amplitude.adenosine diphosphate induced | Len | Pt | Bld | Qn | MA ADP Bld | ||
| 2021-03-29 | 97020-2 | Maximum amplitude arachidonate induced [Length] in Blood | Maximum clot strength amplitude.arachidonate induced | Len | Pt | Bld | Qn | MA AA Bld | ||
| 2021-03-29 | 97021-0 | Reduction in kaolin induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude | Reduction in clot strength.kaolin induced^30M post maximum clot amplitude | LenFr | Pt | Bld | Qn | Fibrinolysis of kaolin ind clot 30M p MA | ||
| 2021-03-29 | 97022-8 | Clot strength arachidonate inhibited [Length fraction] in Blood by calculation | Clot strength.arachidonate inhibited | LenFr | Pt | Bld | Qn | Calculated | Clot strength AA inhib LenFr Bld Calc | |
| 2021-03-26 | 96987-3 | Mass vaccination status [CDC Emergency Operations Centers] | Mass vaccination status | - | Pt | ^Event | - | CDC.EOC | ||
| 2021-03-26 | 96988-1 | Vaccine CVX code | CVX code | ID | Pt | Vaccine | Nom | Vaccine CVX code | ||
| 2021-03-26 | 96989-9 | Vaccine MVX code | MVX code | ID | Pt | Vaccine | Nom | Vaccine MVX code | ||
| 2021-03-26 | 96990-7 | Vaccine administration location | Vaccine administration location | Type | Pt | ^Event | Nom | Vaccine administration loc | ||
| 2021-03-26 | 96991-5 | Vaccine administration county [Location] | Vaccine administration county | Loc | Pt | ^Event | Nom | Vaccine administration county | ||
| 2021-03-26 | 96992-3 | State where vaccine was administered | Vaccine administration state | Loc | Pt | ^Event | Nom | Vaccine administration state | ||
| 2021-03-26 | 96993-1 | Federal agency code | Federal agency code | ID | Pt | Agency | Nom | Federal agency code | ||
| 2021-03-26 | 96994-9 | Vaccine doses distributed [#] | Vaccine doses distributed | Num | Pt | ^Event | Qn | Vaccine doses distributed | ||
| 2021-03-26 | 96995-6 | Total vaccine doses distributed per 100,000 population | Vaccine doses distributed/100,000 population | NRto | Pt | ^Event | Qn | Vac doses dist per 100,000 | ||
| 2021-03-26 | 96996-4 | People who have received first dose of vaccine [#] Population | People who have received first dose of vaccine | Num | Pt | ^Population | Qn | People rcvd first dose of vaccine Pop | ||
| 2021-03-26 | 96997-2 | Count of people who initiated vaccination per 100,000 population | People who have received first dose of vaccine/100,000 population | NFr | Pt | ^Population | Qn | People rcvd first dose of vaccine/100,00 | ||
| 2021-03-26 | 96998-0 | Count of people who finalized vaccination in Population | People who are fully vaccinated | Num | Pt | ^Population | Qn | People who fully vaccinated Pop | ||
| 2021-03-26 | 96999-8 | Count of people who finalized vaccination per 100,000 population | People who are fully vaccinated/100,000 population | NFr | Pt | ^Population | Qn | People who fully vaccinated/100,000 pop | ||
| 2021-03-26 | 97000-4 | Vaccine doses distributed for use in long term care facilities [#] | Vaccine doses distributed for use in long term care facilities | Num | Pt | ^Event | Qn | Vaccine doses distributed to LTCFs | ||
| 2021-03-26 | 97001-2 | Vaccine administration tier | Vaccine administration tier | Type | Pt | ^Event | Nom | Vaccine administration tier | ||
| 2021-03-26 | 97002-0 | Number of people in long-term care facilities who have received first dose of vaccine | People in long-term care facilities who have received first dose of vaccine | Num | Pt | ^Population | Qn | # People in LTCFs rcvd 1st dose vaccine | ||
| 2021-03-26 | 97003-8 | Number of people in long-term care facilities who are fully vaccinated | People in long-term care facilities who are fully vaccinated | Num | Pt | ^Population | Qn | # People in LTCFs fully vaccinated | ||
| 2021-03-26 | 97004-6 | Insulin type [Identifier] in Serum or Plasma by LC/MS/MS | Insulin type | Prid | Pt | Ser/Plas | Nom | LC/MS/MS | Insulin Type SerPl LC/MS/MS | |
| 2021-03-24 | 96984-0 | Chromosome analysis in Products of Conception by Microarray | Chromosome analysis | Find | Pt | POC | Doc | Microarray | Chrom analy POC Microarray | |
| 2021-03-24 | 96985-7 | Sex [Type] in Products of Conception by Molecular genetics method | Fetal sex | Type | Pt | POC | Nom | Molgen | Sex POC | |
| 2021-03-23 | 96959-2 | Cholesterol.in LDL.small dense [Moles/volume] in Serum or Plasma | Cholesterol.in LDL.small dense | SCnc | Pt | Ser/Plas | Qn | Chol.in LDL.small dense SerPl-sCnc | ||
| 2021-03-23 | 96960-0 | Varicella zoster virus IgM Ab index [Units/volume] in Serum and CSF | Varicella zoster virus Ab.IgM Index | ACnc | Pt | Ser+CSF | Qn | VZV IgM Index Ser+CSF-aCnc | ||
| 2021-03-23 | 96961-8 | Varicella zoster virus IgG Ab index [Units/volume] in Serum and CSF | Varicella zoster virus Ab.IgG Index | ACnc | Pt | Ser+CSF | Qn | VZV IgG Index Ser+CSF-aCnc | ||
| 2021-03-23 | 96962-6 | Bordetella pertussis.pertussis toxin promoter region [Presence] in Lower respiratory specimen by NAA with probe detection | Bordetella pertussis.pertussis toxin promoter region | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | B pert.PT Prmt Lower resp Ql NAA+probe | |
| 2021-03-23 | 96963-4 | Grimontia holisae and Vibrio fluvialis and Vibrio harveyi DNA [Identifier] in Specimen by NAA with probe detection | Grimontia holisae & Vibrio fluvialis & Vibrio harveyi DNA | Prid | Pt | XXX | Nom | Probe.amp.tar | G. holisae + V. fluvialis + harveyi DNA | |
| 2021-03-23 | 96964-2 | EZH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | EZH2 gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | EZH2 gene Mut Anl Bld/T | |
| 2021-03-23 | 96965-9 | CARD11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | CARD11 gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | CARD11 Mut Anl Bld/T | |
| 2021-03-23 | 96966-7 | CD79A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | CD79A gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | CD79A Mut Anl Bld/T | |
| 2021-03-23 | 96967-5 | CD79B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | CD79B gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | CD79B Mut Anl Bld/T | |
| 2021-03-23 | 96968-3 | TNFAIP3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | TNFAIP3 gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | TNFAIP3 Mut Anl Bld/T | |
| 2021-03-23 | 96969-1 | MYD88 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | MYD88 gene targeted mutation analysis | Prid | Pt | Bld/Tiss | Nom | Molgen | MYD88 Mut Anl Bld/T | |
| 2021-03-23 | 96970-9 | TP53 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal | TP53 gene deletion+duplication | Prid | Pt | Bld/Tiss | Nom | Molgen | TP53 gene Del+Dup Bld/T | |
| 2021-03-23 | 96971-7 | STK11 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal | STK11 gene deletion+duplication | Prid | Pt | Bld/Tiss | Nom | Molgen | STK11 gene Del+Dup Bld/T | |
| 2021-03-23 | 96972-5 | PTEN gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal | PTEN gene deletion+duplication | Prid | Pt | Bld/Tiss | Nom | Molgen | PTEN gene Del+Dup Bld/T | |
| 2021-03-23 | 96973-3 | CDH1 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal | CDH1 gene deletion+duplication | Prid | Pt | Bld/Tiss | Nom | Molgen | CDH1 gene Del+Dup Bld/T | |
| 2021-03-23 | 96974-1 | PALB2 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal | PALB2 gene deletion+duplication | Prid | Pt | Bld/Tiss | Nom | Molgen | PALB2 Del+Dup Bld/T | |
| 2021-03-23 | 96975-8 | Sub-maximal exercise stress test study report | Sub-maximal exercise stress test study report | Find | Pt | {Setting} | Doc | {Role} | SubMax Ex Stress Test Report | |
| 2021-03-23 | 96976-6 | Carbon dioxide end tidal baseline - sub-maximal exercise delta | Carbon dioxide^at end expiration-Carbon dioxide^at end expiration+W sub-maximal exercise | PPresDiff | Pt | Exhl gas | Qn | pCO2 baseline-SubMx Exer delta | ||
| 2021-03-23 | 96977-4 | Noninvasive prenatal fetal aneuploidy panel - Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA | Noninvasive prenatal fetal aneuploidy panel | - | Pt | WBC.DNA+Plas.cfDNA | - | Dosage of chromosome specific cf DNA | NIP fet aneu Pnl WBC.DNA+cfDNA | |
| 2021-03-23 | 96978-2 | Noninvasive prenatal fetal aneuploidy and 22q11.2 deletion panel - Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA | Noninvasive prenatal fetal aneuploidy & 22q11.2 deletion panel | - | Pt | WBC.DNA+Plas.cfDNA | - | Dosage of chromosome specific cf DNA | NIP aneu + 22q11.2 Pnl WBC.DNA+cfDNA | |
| 2021-03-23 | 96979-0 | Trisomy 13, trisomy 18 or triploidy risk [Interpretation] in Plasma cell-free+WBC DNA Qualitative by calculation | Fetal trisomy 13+trisomy 18+triploidy risk | Imp | Pt | WBC.DNA+Plas.cfDNA | Ord | Calculated | T13+T18+Trip risk WBC.DNA+cfDNA Calc-Imp | |
| 2021-03-23 | 96980-8 | Comment on overall fetal aneuploidy risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative | Comment on overall fetal aneuploidy risk | Txt | Pt | WBC.DNA+Plas.cfDNA | Nar | Dosage of chromosome specific cf DNA | Comment aneu risk WBC.DNA+cfDNA | |
| 2021-03-23 | 96981-6 | Trisomy 13, trisomy 18 or triploidy risk [Likelihood] in Plasma cell-free+WBC DNA by calculation | Fetal trisomy 13+trisomy 18+triploidy risk | Likelihood | Pt | WBC.DNA+Plas.cfDNA | Qn | Calculated | T13+T18+Trip risk WBC.DNA+cfDNA Calc | |
| 2021-03-19 | 96935-2 | Heart rate unspecified time minimum by Pedometer | Heart rate | NRat | XXX^min | Arterial system | Qn | Pedometer | Heart rate ?Tm Min Pedometer | |
| 2021-03-18 | 96912-1 | Calculated CT global noise | CT global noise | Rden | Pt | Study | Qn | Calculated | Calc CT global noise | |
| 2021-03-18 | 96913-9 | Calculated CT size-adjusted dose | CT size-adjusted dose | EngCnt | Pt | Study | Qn | Calculated | Calc CT size-adj dose | |
| 2021-03-18 | 96914-7 | CT dose and image quality category | CT dose & image quality category | Type | Pt | Study | Nom | CT dose + image qual | ||
| 2021-03-18 | 96915-4 | CT quality measure out of range | CT quality measure out of range | Find | Pt | Study | Ord | CT qual meas out of range | ||
| 2021-03-18 | 96916-2 | CT Average diameter on axial mid-scan image | Average diameter on axial mid-scan image | Len | Pt | ^Patient | Qn | CT | CT Avg diam axial mid-scan | |
| 2021-03-18 | 96917-0 | CT Average diameter on frontal scout image | Average diameter on frontal scout image | Len | Pt | ^Patient | Qn | CT | CT Avg diam frontal scout | |
| 2021-03-18 | 96918-8 | Fodrin alpha subunit IgA Ab [Units/volume] in Serum or Plasma by Immunoassay | Fodrin.alpha subunit Ab.IgA | ACnc | Pt | Ser/Plas | Qn | IA | Fodrin alpha IgA SerPl IA-aCnc | |
| 2021-03-18 | 96919-6 | Homogenous nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.homogeneous | Titr | Pt | CSF | Qn | IF | ANA Homogen Titr CSF IF | |
| 2021-03-18 | 96920-4 | Nucleolar nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.nucleolar | Titr | Pt | CSF | Qn | IF | ANA nucleolar Titr CSF IF | |
| 2021-03-18 | 96921-2 | Speckled nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.speckled | Titr | Pt | CSF | Qn | IF | ANA Speckled Titr CSF IF | |
| 2021-03-18 | 96922-0 | Spindle fibers nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.spindle fibers | Titr | Pt | CSF | Qn | IF | ANA spindle fibers Titr CSF IF | |
| 2021-03-18 | 96923-8 | Smooth nuclear envelope nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.smooth nuclear envelope | Titr | Pt | CSF | Qn | IF | ANA smooth nucl env Titr CSF IF | |
| 2021-03-18 | 96924-6 | Intercellular bridge nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.intercellular bridge | Titr | Pt | CSF | Qn | IF | ANA intercell bridge Titr CSF IF | |
| 2021-03-18 | 96925-3 | Nuclear dots nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.nuclear dots | Titr | Pt | CSF | Qn | IF | ANA nuclear dots Titr CSF IF | |
| 2021-03-18 | 96927-9 | Centrosomal nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence | Nuclear Ab pattern.centrosomal | Titr | Pt | CSF | Qn | IF | ANA centrosomal Titr CSF IF | |
| 2021-03-18 | 96926-1 | PCNA extractable nuclear Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | PCNA extractable nuclear Ab | Titr | Pt | CSF | Qn | IF | ENA PCNA Ab Titr CSF IF | |
| 2021-03-18 | 96928-7 | Fodrin alpha subunit IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | Fodrin.alpha subunit Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | Fodrin alpha IgG SerPl IA-aCnc | |
| 2021-03-17 | 96909-7 | Cenobamate [Mass/volume] in Serum or Plasma by Confirmatory method | Cenobamate | MCnc | Pt | Ser/Plas | Qn | Confirm | Cenobamate SerPl Cfm-mCnc | |
| 2021-03-17 | 96910-5 | Acanthamoeba sp and Naegleria fowleri and Balamuthia mandrillaris DNA panel - Specimen | Acanthamoeba sp & Naegleria fowleri & Balamuthia mandrillaris DNA panel | - | Pt | XXX | - | Free-living amoeba Pnl Spec | ||
| 2021-03-17 | 96911-3 | Delta aminolevulinate and porphobilinogen panel - Serum or Plasma | Delta aminolevulinate & porphobilinogen panel | - | Pt | Ser/Plas | - | D-ALA + PBG Pnl SerPl | ||
| 2021-03-05 | 96893-3 | ERBB2 gene duplication in Tumor by FISH | ERBB2 gene duplication | Find | Pt | Tumor | Doc | FISH | ERBB2 gene Dp Tumor FISH | |
| 2021-02-24 | 96830-5 | Specimen source [Identifier] from Donor | Specimen source | Prid | Pt | XXX^Donor | Nom | Specimen source from Donor | ||
| 2021-02-24 | 96841-2 | Tobacco, Alcohol, Prescription medications, and other Substance use screen [TAPS] | Tobacco, Alcohol, Prescription medications, and other Substance use screen | - | 12Mo | ^Patient | - | TAPS | ||
| 2021-02-24 | 96842-0 | How often have you used any tobacco product in past 12 months | How often have you used any tobacco product in past 12Mo | NRat | 12Mo | ^Patient | Ord | Tobacco freq 12Mo | ||
| 2021-02-24 | 96843-8 | How often have you used illegal or recreational drugs in past 12 months | How often have you used illegal or recreational drugs in past 12Mo | NRat | 12Mo | ^Patient | Ord | Drug use freq 12Mo | ||
| 2021-02-24 | 96845-3 | Tobacco, Alcohol, Prescription medications, and other Substance use assessment [TAPS] | Tobacco, Alcohol, Prescription medications, and other Substance use assessment | - | 3Mo | ^Patient | - | TAPS | ||
| 2021-02-24 | 96844-6 | How often have you used any prescription medications just for the feeling, more than prescribed or that were not prescribed for you in past 12 months [TAPS] | How often have you used any prescription medications just for the feeling, more than prescribed or that were not prescribed for you in past 12Mo | NRat | 12Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96846-1 | Smoked at least one cigarette containing tobacco in past 3 months | Smoked at least one cigarette containing tobacco in past 3Mo | Find | 3Mo | ^Patient | Ord | Smkd 1+ cigarette past 3Mo | ||
| 2021-02-24 | 96847-9 | Smoked more than 10 cigarettes per day in past 3 months | Smoked more than 10 cigarettes per D in past 3Mo | Find | 3Mo | ^Patient | Ord | Smkd >10 cig D past 3Mo | ||
| 2021-02-24 | 96848-7 | Smoked cigarette within 30M after waking in past 3 months | Smoked cigarette within 30M after waking in past 3Mo | Find | 3Mo | ^Patient | Ord | Smk cig w/in 30M wake past 3Mo | ||
| 2021-02-24 | 96849-5 | At least one drink in past 3 months | At least one drink in past 3Mo | Find | 3Mo | ^Patient | Ord | 1+ drink past 3Mo | ||
| 2021-02-24 | 96850-3 | Four or more drinks in one day in the past 3 months | Four or more drinks in 1D in the past 3Mo | Find | 3Mo | ^Patient | Ord | 4+ drinks 1D past 3Mo | ||
| 2021-02-24 | 96851-1 | Five or more drinks in one day in the past 3 months | Five or more drinks in 1D in the past 3Mo | Find | 3Mo | ^Patient | Ord | 5+ drinks 1D past 3Mo | ||
| 2021-02-24 | 96852-9 | Have you tried and failed to control, cut down or stop drinking in past 3 months [TAPS] | Have you tried and failed to control, cut down or stop drinking in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96853-7 | Has anyone expressed concern about your drinking in past 3 months [TAPS] | Has anyone expressed concern about your drinking in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96854-5 | Used marijuana in past 3 months | Used marijuana in past 3Mo | Find | 3Mo | ^Patient | Ord | Used marijuana past 3Mo | ||
| 2021-02-24 | 96855-2 | Have you had a strong desire or urge to use marijuana at least once a week or more often in past 3 months [TAPS] | Have you had a strong desire or urge to use marijuana at least once a week or more often in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96857-8 | Used cocaine, crack, or methamphetamine in past 3 months | Used cocaine, crack, or methamphetamine in past 3Mo | Find | 3Mo | ^Patient | Ord | Used cocaine/crack/meth past 3Mo | ||
| 2021-02-24 | 96856-0 | Has anyone expressed concern about your use of marijuana in past 3 months [TAPS] | Has anyone expressed concern about your use of marijuana in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96858-6 | Used cocaine, crack, or methamphetamine at least once a week in past 3 months | Used cocaine, crack, or methamphetamine at least once a week in past 3Mo | Find | 3Mo | ^Patient | Ord | Used cocaine/crack/meth once W past 3Mo | ||
| 2021-02-24 | 96859-4 | Has anyone expressed concern about your use of cocaine, crack, or methamphetamine (crystal meth) in past 3 months [TAPS] | Has anyone expressed concern about your use of cocaine, crack, or methamphetamine in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96860-2 | Used heroin in past 3 months | Used heroin in past 3Mo | Find | 3Mo | ^Patient | Ord | Used heroin past 3Mo | ||
| 2021-02-24 | 96861-0 | Have you tried and failed to control, cut down or stop using heroin in past 3 months [TAPS] | Have you tried and failed to control, cut down or stop using heroin in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96862-8 | Has anyone expressed concern about your use of heroin in past 3 months [TAPS] | Has anyone expressed concern about your use of heroin in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96863-6 | Used prescription opiate pain reliever not as prescribed or not prescribed for you in past 3 months | Used prescription opiate pain reliever not as prescribed or not prescribed for you in past 3Mo | Find | 3Mo | ^Patient | Ord | Misused opiates past 3Mo | ||
| 2021-02-24 | 96864-4 | Have you tried and failed to control, cut down or stop using an opiate pain reliever in past 3 months [TAPS] | Have you tried and failed to control, cut down or stop using an opiate pain reliever in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96865-1 | Has anyone expressed concern about your use of an opiate pain reliever in past 3 months [TAPS] | Has anyone expressed concern about your use of an opiate pain reliever in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96866-9 | Used medication for anxiety or sleep not as prescribed or not prescribed for you in past 3 months | Used medication for anxiety or sleep not as prescribed or not prescribed for you in past 3Mo | Find | 3Mo | ^Patient | Ord | Misused anxiety/sleep meds past 3Mo | ||
| 2021-02-24 | 96867-7 | Have you had a strong desire or urge to use medications for anxiety or sleep at least once a week or more often in past 3 months [TAPS] | Have you had a strong desire or urge to use medications for anxiety or sleep at least once a week or more often in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96869-3 | Used medication for ADHD not as prescribed or not prescribed for you in past 3 months | Used medication for ADHD not as prescribed or not prescribed for you in past 3Mo | Find | 3Mo | ^Patient | Ord | Misused ADHD meds past 3Mo | ||
| 2021-02-24 | 96868-5 | Has anyone expressed concern about your use of medication for anxiety or sleep in past 3 months [TAPS] | Has anyone expressed concern about your use of medication for anxiety or sleep in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96870-1 | Used medication for ADHD not as prescribed or not prescribed for you at least once a week in past 3 months | Used medication for ADHD not as prescribed or not prescribed for you at least once a week in past 3Mo | Find | 3Mo | ^Patient | Ord | Misused ADHD meds once W past 3Mo | ||
| 2021-02-24 | 96872-7 | Used other illegal or recreational drug in past 3 months TAPS | Used other illegal or recreational drug in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | Other illegal/recreation drug past 3Mo | |
| 2021-02-24 | 96871-9 | Has anyone expressed concern about your use of a medication for ADHD (for example, Adderall or Ritalin) in past 3 months [TAPS] | Has anyone expressed concern about your use of a medication for ADHD in past 3Mo | Find | 3Mo | ^Patient | Ord | TAPS | ||
| 2021-02-24 | 96873-5 | Illegal or recreational drug(s) used in past 3 months | Illegal or recreational drug(s) used in past 3Mo | Find | 3Mo | ^Patient | Nom | |||
| 2021-02-23 | 96823-0 | Respiration [Score] SOFA | Respiration | Score | Pt | ^Patient | Qn | SOFA | Respiration Score SOFA | |
| 2021-02-23 | 96824-8 | Coagulation [Score] SOFA | Coagulation | Score | Pt | ^Patient | Qn | SOFA | Coag Score SOFA | |
| 2021-02-23 | 96825-5 | Liver [Score] SOFA | Liver | Score | Pt | ^Patient | Qn | SOFA | Liver Score SOFA | |
| 2021-02-23 | 96826-3 | Cardiovascular [Score] SOFA | Cardiovascular | Score | Pt | ^Patient | Qn | SOFA | Cardio Score SOFA | |
| 2021-02-23 | 96827-1 | Central nervous system [Score] SOFA | Central nervous system | Score | Pt | ^Patient | Qn | SOFA | CNS Score SOFA | |
| 2021-02-23 | 96828-9 | Renal [Score] SOFA | Renal | Score | Pt | ^Patient | Qn | SOFA | Renal Score SOFA | |
| 2021-02-19 | 96798-4 | Cortisol, glucose, and somatotropin post arginine stimulation panel - Serum or Plasma | Cortisol & glucose & somatotropin post arginine stimulation panel | - | Pt | Ser/Plas | Qn | Cortisol+glucose+GH p arginine Pnl SerPl | ||
| 2021-02-19 | 96799-2 | Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose arginine | Glucose^30M post dose arginine | MCnc | Pt | Ser/Plas | Qn | Glucose 30M p Arg SerPl-mCnc | ||
| 2021-02-19 | 96800-8 | Glucose [Mass/volume] in Serum or Plasma --1 hour post dose arginine | Glucose^1H post dose arginine | MCnc | Pt | Ser/Plas | Qn | Glucose 1h p Arg SerPl-mCnc | ||
| 2021-02-19 | 96801-6 | Cortisol [Mass/volume] in Serum or Plasma --1 hour post dose arginine | Cortisol^1H post dose arginine | MCnc | Pt | Ser/Plas | Qn | Cortis 1h p Arg SerPl-mCnc | ||
| 2021-02-19 | 96802-4 | Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine | Glucose^1.5H post dose arginine | MCnc | Pt | Ser/Plas | Qn | Glucose 1.5h p Arg SerPl-mCnc | ||
| 2021-02-19 | 96803-2 | 24 hour predicted protein [Mass/time] based on random Urine by calculation | 24H predicted protein | MRat | Pt | Urine | Qn | Calculated | 24H predicted prot Ur Calc-mRate | |
| 2021-02-19 | 96804-0 | 24 hour predicted protein [Mass/time range] based on random Urine by calculation | 24H predicted protein | MRatRange | Pt | Urine | Qn | Calculated | 24H predicted prot mRatRange Ur Calc | |
| 2021-02-19 | 96805-7 | Cobalamin (Vitamin B12) and folate panel - Serum | Cobalamins & folate panel | - | Pt | Ser | Qn | Vit B12 + folate Pnl Ser | ||
| 2021-02-19 | 96806-5 | Ginseng IgE Ab [Units/volume] in Serum | Panax ginseng Ab.IgE | ACnc | Pt | Ser | Qn | Ginseng IgE Qn | ||
| 2021-02-19 | 96807-3 | Vancomycin IgE Ab [Units/volume] in Serum | Vancomycin Ab.IgE | ACnc | Pt | Ser | Qn | Vancomycin IgE Qn | ||
| 2021-02-19 | 96808-1 | Thiamine IgE Ab [Units/volume] in Serum | Thiamine Ab.IgE | ACnc | Pt | Ser | Qn | Vit B1 IgE Qn | ||
| 2021-02-19 | 96809-9 | Cyanocobalamin IgE Ab [Units/volume] in Serum | Cyanocobalamin Ab.IgE | ACnc | Pt | Ser | Qn | Cyanocobalamin IgE Qn | ||
| 2021-02-19 | 96810-7 | White willow IgE Ab [Units/volume] in Serum | Salix alba Ab.IgE | ACnc | Pt | Ser | Qn | White willow IgE Qn | ||
| 2021-02-19 | 96811-5 | Heather IgE Ab [Units/volume] in Serum | Calluna vulgaris Ab.IgE | ACnc | Pt | Ser | Qn | Heather IgE Qn | ||
| 2021-02-19 | 96812-3 | Chervil IgE Ab [Units/volume] in Serum | Anthriscus cerefolium Ab.IgE | ACnc | Pt | Ser | Qn | Chervil IgE Qn | ||
| 2021-02-19 | 96813-1 | Goat milk cheese IgE Ab [Units/volume] in Serum | Goat milk cheese Ab.IgE | ACnc | Pt | Ser | Qn | Goat milk cheese IgE Qn | ||
| 2021-02-19 | 96814-9 | Sheep milk cheese IgE Ab [Units/volume] in Serum | Sheep milk cheese Ab.IgE | ACnc | Pt | Ser | Qn | Sheep milk cheese IgE Qn | ||
| 2021-02-19 | 96815-6 | Piper gurnard IgE Ab [Units/volume] in Serum | Trigla spp Ab.IgE | ACnc | Pt | Ser | Qn | Piper gurnard IgE Qn | ||
| 2021-02-19 | 96816-4 | Tetracaine IgE Ab [Units/volume] in Serum | Tetracaine Ab.IgE | ACnc | Pt | Ser | Qn | Tetracaine IgE Qn | ||
| 2021-02-19 | 96817-2 | Thermoactinomyces candidus IgE Ab [Units/volume] in Serum | Thermoactinomyces candidus Ab.IgE | ACnc | Pt | Ser | Qn | T candidus IgE Qn | ||
| 2021-02-19 | 96818-0 | English yew IgE Ab [Units/volume] in Serum | Taxus baccata Ab.IgE | ACnc | Pt | Ser | Qn | English yew IgE Qn | ||
| 2021-02-19 | 96819-8 | Roxithromycin IgE Ab [Units/volume] in Serum | Roxithromycin Ab.IgE | ACnc | Pt | Ser | Qn | Roxithromycin IgE Qn | ||
| 2021-02-19 | 96820-6 | Arugula IgE Ab [Units/volume] in Serum | Eruca vesicaria subspecies sativa Ab.IgE | ACnc | Pt | Ser | Qn | Arugula IgE Qn | ||
| 2021-02-19 | 96821-4 | Propylparaben IgE Ab [Units/volume] in Serum | Propylparaben Ab.IgE | ACnc | Pt | Ser | Qn | Propylparaben IgE Qn | ||
| 2021-02-19 | 96822-2 | Spurge IgE Ab [Units/volume] in Serum | Euphorbia spp. Ab.IgE | ACnc | Pt | Ser | Qn | Spurge IgE Qn | ||
| 2021-02-17 | 96795-0 | Hexacarboxylporphyrins [Moles/volume] in Urine | Hexacarboxylporphyrins | SCnc | Pt | Urine | Qn | Hexa-CPs Ur-sCnc | ||
| 2021-02-16 | 96793-5 | Softwood Mix (Beech+Pine+Red cedar+Silver fir) IgE Ab [Units/volume] in Serum by Multidisk | (Fagus grandifolia+Pinus strobus+Thuja plicata+Abies alba) Ab.IgE | ACnc | Pt | Ser | Qn | Multidisk | Softwood Mix IgE Qn | |
| 2021-02-16 | 96794-3 | Hardwood Mix (Oak+Mahogany+West Red Cedar+Abachi) IgE Ab [Units/volume] in Serum by Multidisk | (Quercus alba+Swietenia+Thuja plicata+Triplochiton scleroxylon) Ab.IgE | ACnc | Pt | Ser | Qn | Multidisk | Hardwood Mix IgE Qn | |
| 2021-02-12 | 96789-3 | Sequential Organ Failure Assessment SOFA | Sequential Organ Failure Assessment | - | Pt | ^Patient | - | SOFA | SOFA | |
| 2021-02-12 | 96790-1 | SOFA Total Score | SOFA total score | Score | Pt | ^Patient | Qn | SOFA | SOFA | |
| 2021-02-12 | 96791-9 | Quick SOFA score SOFA.quick | Quick SOFA score | Score | Pt | ^Patient | Qn | SOFA.quick | QSOFA QSOFA | |
| 2021-02-12 | 96792-7 | Modified SOFA score | Modified SOFA score | Score | Pt | ^Patient | Qn | SOFA.modified | MSOFA | |
| 2021-02-10 | 96777-8 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | Accountable health communities health-related social needs screening tool | - | Pt | ^Patient | - | |||
| 2021-02-10 | 96778-6 | Problems where you live | Problems where you live | Find | Pt | ^Patient | Nom | |||
| 2021-02-10 | 96779-4 | Has the electric, gas, oil, or water company threatened to shut off services in your home in past 12 months | Has the electric, gas, oil, or water company threatened to shut off services in your home in past 12 Mo | Find | 12Mo | ^Patient | Ord | |||
| 2021-02-10 | 96780-2 | Wants help finding or keeping work or a job | Wants help finding or keeping work or a job | Find | Pt | ^Patient | Ord | |||
| 2021-02-10 | 96781-0 | Able to get help when needed | Able to get help when needed | Find | Pt | ^Patient | Ord | |||
| 2021-02-10 | 96782-8 | Wants help with school or training | Wants help with school or training | Find | Pt | ^Patient | Ord | |||
| 2021-02-09 | 96768-7 | Pregnancy outcome related to illness or condition | Pregnancy outcome related to illness or condition | Find | Pt | ^Patient | Nom | Pregnancy outcome | ||
| 2021-02-09 | 96769-5 | Type of immunosuppressive medication used | Type of immunosuppressive medication used | Type | Pt | ^Patient | Nom | Immunosuppressive medication | ||
| 2021-02-09 | 96770-3 | Fresh water supply was treated prior to use | Fresh water supply was treated prior to use | Find | Pt | ^Patient | Ord | Fresh water supply was treated | ||
| 2021-02-05 | 96767-9 | Grooming - functional ability | Grooming - functional ability | Find | Pt | ^Patient | Ord | Grooming ability | ||
| 2021-02-02 | 96758-8 | Stairs - functional ability | Stairs - functional ability | Find | Pt | ^Patient | Ord | Stairs ability | ||
| 2021-02-02 | 96759-6 | Bowel control - functional ability | Bowel control - functional ability | Find | Pt | ^Patient | Ord | Bowel control ability | ||
| 2021-02-02 | 96760-4 | Bladder control - functional ability | Bladder control - functional ability | Find | Pt | ^Patient | Ord | Bladder control ability | ||
| 2021-02-02 | 96761-2 | Total score Barthel Index | Total score | Score | Pt | ^Patient | Qn | Barthel Index | Total score Barthel Index | |
| 2021-02-02 | 96762-0 | Barthel index panel | Barthel index panel | - | Pt | ^Patient | - | Barthel Index | Barthel index | |
| 2021-01-25 | 96754-7 | Mycobacterium tuberculosis stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood | Mycobacterium tuberculosis stimulated gamma interferon release by T-cells^^corrected for background | ACnc | Pt | Bld | Qn | M TB IFN-g T-cells bckgrd cor Bld-aCnc | ||
| 2021-01-20 | 96753-9 | Would like help with paying heating AndOr electricity bill Caregiver | Would like help with paying heating &or electricity bill | Find | Pt | ^Caregiver | Ord | |||
| 2021-01-13 | 96750-5 | Comorbidity score | Comorbidity score | Score | Pt | ^Patient | Ord | Comorbidity score | ||
| 2021-01-07 | 96743-0 | Cannot read or write in primary language | Cannot read or write in primary language | Find | Pt | ^Patient | Ord | Cannot read/write prim lang | ||
| 2021-01-07 | 96744-8 | Intervention or enabling service minutes [#] | Intervention or enabling service minutes | Num | Pt | ^Patient | Qn | Interv/enab serv min | ||
| 2021-01-07 | 96746-3 | Appointment type | Appointment type | Type | Pt | ^Patient | Nom | Appt type | ||
| 2021-01-07 | 96747-1 | Service provided in a language other than English | Service provided in a language other than English | Find | Pt | ^Patient | Ord | Serv prov not in Eng | ||
| 2021-01-07 | 96745-5 | Intervention or enabling service group size | Intervention or enabling service group size | Type | Pt | ^Patient | Nom | I/E service grp size | ||
| 2021-01-07 | 96748-9 | Interventions or enabling services provided | Interventions or enabling services provided | Type | Pt | ^Patient | Nom | I/E services provided | ||
| 2021-01-07 | 96749-7 | Association of Asian Pacific Community Health Organizations enabling services and social intervention panel AAPCHO | Association of Asian Pacific Community Health Organizations enabling services and social intervention panel | - | Pt | ^Patient | - | AAPCHO | AAPCHO I/E Pnl | |
| 2020-11-18 | 96569-9 | LACE index panel | LACE index panel | - | Pt | ^Patient | - | LACE index | LACE index panel | |
| 2020-11-18 | 96571-5 | Admitted via emergency department | Admitted via emergency department | Find | Pt | ^Patient | Ord | ED Admit | ||
| 2020-11-18 | 96574-9 | LACE index score LACE index | LACE index score | Score | Pt | ^Patient | Qn | LACE index | LACE score LACE | |
| 2020-11-16 | 96433-8 | Would like help finding daycare for child Caregiver | Would like help finding daycare for child | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96434-6 | Always has enough food for family Caregiver | Always has enough food for family | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96435-3 | At risk of having utilities shut off in the next week Caregiver | At risk of having utilities shut off in the next week | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96436-1 | Trouble paying heating bill AndOr electricity bill Caregiver | Trouble paying heating bill &or electricity bill | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96437-9 | Needs help getting food for family for tonight Caregiver | Needs help getting food for family for tonight | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96438-7 | Would like help getting food for family Caregiver | Would like help getting food for family | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96439-5 | Emergent risk of becoming homeless Caregiver | Emergent risk of becoming homeless | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96440-3 | Would like help for being at risk of becoming homeless Caregiver | Would like help for being at risk of becoming homeless | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96441-1 | At risk of becoming homeless Caregiver | At risk of becoming homeless | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96442-9 | Needs daycare for child Caregiver | Needs daycare for child | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96443-7 | Would like help finding employment AndOr job training Caregiver | Would like help finding employment &or job training | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96444-5 | Has a job Caregiver | Has a job | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96445-2 | Would like help to get a GED Caregiver | Would like help to get a GED | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96446-0 | High school degree Caregiver | High school degree | Find | Pt | ^Caregiver | Ord | |||
| 2020-11-16 | 96447-8 | WE CARE Survey [WE CARE] Caregiver | WE CARE Survey | - | Pt | ^Caregiver | - | WE CARE |
TIP Click on headings to sort table by that column. Hold down Shift and click additional headings to add to sorting.
TIP In your web browser, use ControlF (or ⌘F on Mac) to find text on this page.
Receive notices of new and revised Special Use prerelease codes
Sign up to receive an email notification when new prerelease Special Use LOINC terms are created or revised.
For timely updates, follow @LOINC on Twitter. An RSS feed of new Special Use terms is also available.